8-K: TOMI Environmental Solutions Reports Mixed Q4 and Year-End 2024 Financial Results, Sees Strong Start to 2025

TOMI Environmental Solutions reports a 5% increase in annual revenue for 2024, but faces a GAAP net loss due to significant non-cash charges, while preliminary Q1 2025 revenues show a promising 42% increase.

Summary

• TOMI Environmental Solutions, Inc. announced its fourth quarter and year-end 2024 financial results.
• Annual revenue increased by 5% year-over-year, reaching $7,739,000 in 2024 compared to $7,355,000 in 2023.
• The company experienced a GAAP net loss of $(4,477,000) for the year, or $(0.22) per share, compared to a loss of $(3,403,000) or $(0.17) per share in the previous year.
• Non-GAAP net loss was $(2,050,000) or $(0.10) per share, compared to $(2,838,000) or $(0.14) per share in the prior year.
• For the fourth quarter, net sales were $1,069,000 compared to $1,528,000 in the same period of 2023.
• The GAAP net loss for the quarter was $(3,256,000), or $(0.16) per share, compared to a loss of $(1,226,000), or $(0.06) per share in the prior year.
• Preliminary Q1 2025 revenues are up 42% compared to Q1 2024, reaching approximately $1,577,000.
• Sales backlog has increased to $1,232,000 as of March 31, 2025, a 40% increase from December 31, 2024.
• The company is seeing a preliminary quarter over quarter growth in solution sales of approximately 200%.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While there's revenue growth and positive preliminary Q1 2025 results, the significant GAAP net loss and decreased gross margin temper the overall outlook. The company's forward-looking statements suggest optimism, but risks remain.

Positives

• Annual revenue increased by 5% year-over-year.
• Preliminary Q1 2025 revenues show a 42% increase compared to the same period last year.
• Sales backlog increased by 40% from the end of 2024 to March 31, 2025.
• International revenue grew by 33% in 2024.
• SteraMist product-based and service-based revenues both saw increases in 2024.
• The company expanded its partnerships and customer base globally.

Negatives

• The company reported a GAAP net loss of $(4,477,000) for the year ended December 31, 2024.
• GAAP gross margin decreased from 58% in 2023 to 46% in 2024.
• GAAP operating loss increased from $(3,349,000) in 2023 to $(4,105,000) in 2024.
• Fourth-quarter sales decreased from $1,528,000 in 2023 to $1,069,000 in 2024.
• The GAAP gross margin for the fourth quarter was negative (50%).
• GAAP operating loss for the fourth quarter was $(3,149,000), compared to $(1,171,000) in the prior year.

Risks

• The company's ability to acquire new customers and expand sales is a risk.
• Maintaining and managing growth and generating sales is a potential challenge.
• Reliance on a single or a few products for a majority of revenues poses a risk.
• General business and economic conditions could impact financial performance.
• The preliminary Q1 2025 results are unaudited and subject to adjustment.

Future Outlook

The company expects continued improvement in 2025, driven by strong preliminary Q1 revenues and a sales pick-up in BIT solutions sales.

Management Comments

• Dr. Halden Shane, TOMI's CEO, stated that the company increased year-over-year annual revenue by 5% and expanded its customer base.
• Dr. Shane noted that significant non-cash charges contributed to the GAAP net loss for the quarter and full year.
• Dr. Shane expects continued improvement in 2025 with preliminary Q1 revenues up 42% over last year.

Industry Context

TOMI operates in the disinfection and decontamination industry, providing solutions for various commercial structures. The company's growth in international markets and partnerships indicates a focus on expanding its global presence. The adoption of SteraMist technology by educational institutions highlights the increasing demand for advanced disinfection measures.

Comparison to Industry Standards

• It's difficult to provide a direct comparison to industry standards without knowing the specific market segments TOMI competes in and the financial performance of its direct competitors.
• However, companies like Steris, Ecolab, and Cantel Medical (now part of STERIS) are major players in the broader infection prevention and sterilization market.
• These companies often have higher revenue and profitability due to their scale and diversified product offerings.
• TOMI's focus on Binary Ionization Technology (BIT) and its SteraMist brand differentiates it from some competitors, but it also faces the challenge of educating the market and gaining wider adoption of its technology.

Stakeholder Impact

• Shareholders may be concerned about the GAAP net loss, but encouraged by the preliminary Q1 2025 results.
• Employees may be affected by the company's efforts to improve profitability and manage expenses.
• Customers may benefit from the company's expanded product line and services.
• Suppliers may see increased demand as the company grows its revenue.

Next Steps

• The company will hold a conference call to discuss the results.
• TOMI will continue to nurture partnerships to further develop and strengthen the SteraMist brand in the global market.
• TOMI will focus on driving improving profitability as it moves through 2025.

Key Dates

Keywords

TOMI Environmental Solutions, SteraMist, Financial Results, Disinfection, Decontamination, Revenue, Net Loss, iHP Technology